Selection‐based Design of in silico Dengue Epitope Ensemble Vaccines

David Murphy, Pedro Reche, Darren R Flower

Research output: Contribution to journalArticle


Dengue virus affects approximately 130 countries. 25% of infections result in febrile, self‐limiting illness; heterotypic infection results in potentially fatal Dengue Haemorrhagic Fever or Dengue Shock Syndrome. Only one vaccine is currently available. Its efficacy is very variable. Thus, to target Dengue, we used an innovative immunoinformatic protocol to design a putative epitope ensemble vaccine by selecting an optimal set of highly‐conserved epitopes with experimentally‐verified immunogenicity. From 1597 CD4+ and MHC II epitopes, 6 MHC Class I epitopes (RAVHADMGYW, GPWHLGKLEM, GLYGNGVVTK, NMIIMDEAHF, KTWAYHGSY, WAYHGSYEV) and 9 MHC Class II epitopes (LAKAIFKLTYQNKVV, GKIVGLYGNGVVTTS, AAIFMTATPPGSVEA, AAIFMTATPPGTADA, GKTVWFVPSIKAGND, KFWNTTIAVSMANIF, RAIWYMWLGARYLEF, VGTYGLNTFTNMEVQ, WTLMYFHRRDLRLAA) were selected; this candidate vaccine achieved a world population coverage of 92.49%.
Original languageEnglish
JournalChemical Biology and Drug Design
Early online date25 Nov 2018
Publication statusE-pub ahead of print - 25 Nov 2018

Bibliographical note

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.© 2018 The Authors.

Fingerprint Dive into the research topics of 'Selection‐based Design of in silico Dengue Epitope Ensemble Vaccines'. Together they form a unique fingerprint.

Cite this